SCHEMBL23219210

SCHEMBL23219210

CCOC(=O)c1coc2c(COc3ccccc3)cc(Br)cc12

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.45
MAPT P10636 2/20 0.45
MAPK1 P28482 1/20 0.45
HSD17B10 Q99714 1/20 0.45
MAPK10 P53779 1/20 0.45
MAOB P27338 2/20 0.44
SMN1; SMN2 Q16637 4/20 0.43
ALDH1A1 P00352 1/20 0.42
MEN1 O00255 1/20 0.40
HSP90AA1 P07900 1/20 0.40
KMT2A Q03164 1/20 0.40
TDP1 Q9NUW8 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
GABRA1 P14867 1/20 0.39
GABRB1 P18505 1/20 0.39
GABRA3 P34903 1/20 0.39
GABRB2 P47870 1/20 0.39
KDM4E B2RXH2 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
RXFP1 Q9HBX9 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23218133 0.89 MMP1 (0.41) TSHRMAPTHSD17B10MAOBSMN1; SMN2
SCHEMBL23218838 0.82 ALDH1A1 (0.42) TSHRMAPTMAPK1MAOBSMN1; SMN2
SCHEMBL29853260 0.82 ALDH1A1 (0.42) TSHRMAPTMAPK1MAOBSMN1; SMN2
SCHEMBL23219051 0.79 TBXAS1 (0.39) TSHRMAPTMAPK1HSD17B10MEN1
SCHEMBL29852526 0.79 TBXAS1 (0.39) TSHRMAPTMAPK1HSD17B10MEN1
SCHEMBL29852641 0.79 GABRA1 (0.42) TSHRMAPTMAPK1MAOBSMN1; SMN2
SCHEMBL23218592 0.79 GABRA1 (0.42) TSHRMAPTMAPK1MAOBSMN1; SMN2
SCHEMBL23218947 0.78 ALDH1A1 (0.45) TSHRMAPTMAPK1MAOBSMN1; SMN2
SCHEMBL23218040 0.77 DAO (0.38) MAOBSMN1; SMN2ALDH1A1TDP1L3MBTL1
SCHEMBL23218569 0.76 LMNA (0.46) TSHRMAPTHSD17B10MAOBSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12558341-B2 Oral complement factor D inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2026-02-24 US disclosed
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-06-12 US disclosed
EP-4041238-A1 ORAL COMPLEMENT FACTOR D INHIBITORS Biocryst Pharmaceuticals, Inc. (US) 2022-08-17 EP disclosed
CN-114502168-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-13 CN disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12558341-B2 Oral complement factor D inhibitors CFD, CFH, CFB TSHR 1199/4885MAPT 4793/4885MAPK1 2708/4885
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB TSHR 3148/4885MAPT 3561/4885MAPK1 2267/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.